Innovative Medicine — Selling, marketing and administrative expenses
Johnson & Johnson Innovative Medicine — Selling, marketing and administrative expenses decreased by 15.6% to $2.92B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 29.1%, from $2.26B to $2.92B. Over 3 years (FY 2022 to FY 2025), Innovative Medicine — Selling, marketing and administrative expenses shows an upward trend with a 5.4% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
High spending may be necessary for new product launches, but excessive spending relative to revenue growth may signal inefficiency.
Detailed definition
Captures the operating expenses related to the sales force, marketing campaigns, and administrative support for the Inno...
Peer comparison
Standard 'SG&A' expense allocation for business segments in the pharmaceutical industry.
jnj_segment_innovative_medicine_selling_marketing_and_administrative_expensesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.43B | $2.43B | $2.43B | $2.43B | $2.46B | $2.46B | $2.46B | $2.46B | $2.44B | $2.67B | $2.49B | $3.31B | $2.26B | $2.79B | $2.87B | $3.46B | $2.92B |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +1.3% | +0.0% | +0.0% | +0.0% | -0.9% | +9.3% | -6.5% | +33.0% | -31.7% | +23.4% | +2.9% | +20.5% | -15.6% |
| YoY Change | — | — | — | — | +1.3% | +1.3% | +1.3% | +1.3% | -0.9% | +8.3% | +1.2% | +34.6% | -7.3% | +4.7% | +15.2% | +4.3% | +29.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's innovative medicine — selling, marketing and administrative expenses?
- Johnson & Johnson (JNJ) reported innovative medicine — selling, marketing and administrative expenses of $2.92B in Q1 2026.
- How has Johnson & Johnson's innovative medicine — selling, marketing and administrative expenses changed year-over-year?
- Johnson & Johnson's innovative medicine — selling, marketing and administrative expenses increased by 29.1% year-over-year, from $2.26B to $2.92B.
- What is the long-term trend for Johnson & Johnson's innovative medicine — selling, marketing and administrative expenses?
- Over 3 years (2022 to 2025), Johnson & Johnson's innovative medicine — selling, marketing and administrative expenses has grown at a 5.4% compound annual growth rate (CAGR), from $9.71B to $11.38B.
- What does innovative medicine — selling, marketing and administrative expenses mean?
- The costs of selling, marketing, and managing the Innovative Medicine business.